"Hoping against hope" the Supreme Court is simply signaling a need to provide greater guidance to the Federal Circuit is one way to view the high court's decision to grant cert in Association for Molecular Pathology v. Myriad Genetics Inc., according to Kevin E. Noonan, a partner in the Chicago office of McDonnell Boehnen Hulbert & Berghoff LLP. Read More
Arguments have gone back and forth for some time now on whether cancer cells use a developmental program called the epithelial to mesenchymal transition, or EMT, to metastasize. Read More
As investors continue to digest news regarding FDA concerns about overall survival trends of renal cell carcinoma patients in a Phase III trial with tivozanib, AVEO Oncology Inc. and Astellas Pharma Inc. have begun a Phase II study with the compound in triple-negative breast cancer. Read More
• Genisphere Inc., of Hatfield, Pa., partnered with the Lankenau Institute for Medical Research to develop nanotherapeutic products for cancers and eye diseases. Read More
• Upsher-Smith Laboratories Inc., of San Diego, said Phase I data showing that USL261 (intranasal midazolam) demonstrated that maximum midazolam plasma concentrations were rapidly achieved after dosing, and both midazolam and its metabolite were rapidly eliminated. Read More
• Ipsen SA, of Paris, and Galderma Pharma SA, of Lausanne, Switzerland, said they extended their collaboration for the promotion and distribution of Dysport, Ipsen's botulinum toxin Type A in aesthetic indications, renewing the deal in Brazil and Argentina and adding Australia where Galderma has the exclusive promotion and distribution rights for Dysport in the glabellar lines indication. Read More